Loading ...

Fast insight into nanotechnology

Access easily searchable nanoscience data, synthesis methods and literature

hexadecyloxypropyl tenofovir injectable suspension

Based on

1 Patents
2014 Most recent source

Composition

Image only illustrates the order and placement of components as described in literature.

1

hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine

hexadecyloxypropyl tenofovir CMX-157
Type Single Compound
Formula C28H52N5O5P
Role raw materials

Properties

Applications

Area Application Nanomaterial Variant Source
medicine/veterinary

More information available to subscribers only.

Or, view sample content

Characterization

Biological effects

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
  • hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine
  • polyoxyethylene (20) sorbitan monolaurate
  • water
See all (5)
Product

hexadecyloxypropyl tenofovir injectable suspension

Size: 75 - 646 nm

Medium: parenterally injectable solution

Support: none

Method 2

Type: Physical formation
Source:
Starting materials
  • hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine
  • polyoxyethylene (20) sorbitan monolaurate
  • water
See all (5)
Product

hexadecyloxypropyl tenofovir injectable suspension

Size: 82 - 726 nm

Medium: parenterally injectable solution

Support: none

Method 3

Type: Purification
Source:
Starting materials
  • hexadecyloxypropyl tenofovir injectable suspension
  1. OFk22Et7mi0jsMCYk
Product

hexadecyloxypropyl tenofovir injectable suspension

Size: 75 - 646 nm

Medium: parenterally injectable solution

Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial